Abstract
Aim: Study was aimed to investigate the potential drug–drug interactions between antimalarial candidate 99/411 and antitubercular drug rifampicin. Methods: A single-dose drug-interaction study followed by multiple dose parallel study was designed to estimate the drug–drug interactions. Results: It was found that steady-state pharmacokinetics profile of 99/411 determined after multiple dosing for five successive days was consistent with the single-dose characteristics in both the cases, when 99/411 was given alone and co-administered with rifampicin. Conclusion: The compound was absorbed fast after each dosing and declined up to next 24 h to lower concentration. AUC showed accumulation of 99/411 day by day after multiple dosing, which may affect the therapeutic response of this molecule.
Acknowledgements
The authors acknowledge the Director, CSIR-CDRI and Council for Scientific and Industrial Research (CSIR) for availing all the facilities required for this research work.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.